Log In
Print
BCIQ
Print
Print this Print this
 

KB001

  Manage Alerts
Collapse Summary General Information
Company KaloBios Pharmaceuticals Inc.
DescriptionHumanized high-affinity PEGylated antibody fragment against PcrV (V-antigen) on Pseudomonas aeruginosa
Molecular Target Not available
Mechanism of ActionAntibody
Latest Stage of DevelopmentPhase I/II
IndicationPseudomonas
Partner

Sanofi
 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today